Program
diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine
Also written as “Infanrix hexa”, “DTPa-HBV-IPV/Hib” and “Infanrix™ hexa”.
Its studies are mostly in Hepatitis B · Diphtheria · Streptococcal Infections · Poliomyelitis · Meningococcal Infections, led by 4 companies.
Drug pageDiphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine: every studyAll 29 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKlineits history only | 230 open or running | phase 4since Jan 29, 2008 | Sep 13, 2005 | none ahead |
| Pfizerits history only | 21 open or running | phase 4since Feb 17, 2006 | Feb 17, 2006 | Nov 6, 2028phase 3 · NCT07160244 |
| Merckits history only | 10 open or running | phase 3since Feb 5, 2007 | Feb 5, 2007 | none ahead |
| Sanofiits history only | 11 open or running | phase 2since Oct 16, 2024 | Oct 16, 2024 | May 17, 2027phase 2 · NCT06647407 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 12 studies since Sep 13, 2005.
- Jan 29, 2008Phase 4 study in PoliomyelitisGlaxoSmithKline · NCT00611559 · 283 enrolled · Russian Federation
- Feb 15, 2008Phase 3 study in Streptococcal InfectionsGlaxoSmithKline · NCT00624819 · 524 enrolled · Poland
- Feb 20, 2008Phase 2 study in DiphtheriaGlaxoSmithKline · NCT00627458 · 403 enrolled · Finland
- Sep 12, 2008Phase 4 study in Hepatitis BGlaxoSmithKline · NCT00753649 · 224 enrolled · Canada
- May 12, 2011Phase 3 study in PoliomyelitisGlaxoSmithKline · NCT01353703 · 224 enrolled · India
- Oct 13, 2011Phase 4 study in Hepatitis BGlaxoSmithKline · NCT01457547 · 494 enrolled · Finland, Italy, Sweden
- Oct 13, 2011Phase 2 study in Hepatitis BGlaxoSmithKline · NCT01457495 · 312 enrolled
- Oct 20, 20112 phase 3 studies in Hepatitis BGlaxoSmithKline · NCT01457560, NCT01457508
- Mar 21, 2014Phase 3 study in PoliomyelitisGlaxoSmithKline · NCT02096263 · 585 enrolled · United States
- Mar 19, 2015Phase 4 study in TetanusGlaxoSmithKline · NCT02422264 · 601 enrolled · Australia, Canada, Czechia and more
- Jul 14, 2016Phase 4 study in DiphtheriaGlaxoSmithKline · NCT02853929 · 551 enrolled · Australia, Canada, Czechia and more
- Aug 27, 2020Phase 4 study in DiphtheriaGlaxoSmithKline · NCT04535037 · 500 enrolled · Germany, Italy, Spain
- Oct 16, 2024Sanofi’s first study: phase 2 study in Meningococcal ImmunizationNew to SanofiSanofi · NCT06647407 · 750 enrolled · Brazil, Czechia, Denmark and more
- Aug 14, 2025Phase 3 study in HealthyPfizer · NCT07160244 · 6,000 planned · United States, Argentina, Brazil and more
Ahead
- May 17, 2027Primary completion: phase 2 study in Meningococcal ImmunizationSanofi · NCT06647407
- Nov 6, 2028Primary completion: phase 3 study in HealthyPfizer · NCT07160244
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
Studies
All 27 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07160244Healthy · United States, Argentina, Brazil and more | 3 | Recruiting | Pfizer | Nov 6, 2028 | 6,000 |
| NCT06647407Meningococcal Immunization · Brazil, Czechia, Denmark and more | 2 | Active, not recruiting | Sanofi | May 17, 2027 | 750 |
| NCT04535037Diphtheria · Germany, Italy, Spain | 4 | Completed | GlaxoSmithKline | Jul 25, 2022 | 500 |
| NCT02853929Diphtheria · Australia, Canada, Czechia and more | 4 | Completed | GlaxoSmithKline | Mar 19, 2019 | 551 |
| NCT02422264Tetanus · Australia, Canada, Czechia and more | 4 | Completed | GlaxoSmithKline | Mar 7, 2018 | 601 |
| NCT02096263Poliomyelitis · United States | 3 | Completed | GlaxoSmithKline | Feb 6, 2015 | 585 |
| NCT01457560Hepatitis B | 3 | Completed | GlaxoSmithKline | Apr 2001 | 80 |
| NCT01457508Hepatitis B | 3 | Completed | GlaxoSmithKline | Mar 2000 | 440 |
| NCT01457547Hepatitis B · Finland, Italy, Sweden | 4 | Completed | GlaxoSmithKline | May 2005 | 494 |
| NCT01457495Hepatitis B | 2 | Completed | GlaxoSmithKline | Sep 1999 | 312 |
| NCT01353703Poliomyelitis · India | 3 | Completed | GlaxoSmithKline | Feb 25, 2013 | 224 |
| NCT00753649Hepatitis B · Canada | 4 | Completed | GlaxoSmithKline | Mar 12, 2013 | 224 |
| NCT00627458Diphtheria · Finland | 2 | Completed | GlaxoSmithKline | Aug 18, 2008 | 403 |
| NCT00624819Streptococcal Infections · Poland | 3 | Completed | GlaxoSmithKline | Jun 2, 2008 | 524 |
| NCT00611559Poliomyelitis · Russian Federation | 4 | Completed | GlaxoSmithKline | Jun 25, 2008 | 283 |
| NCT00533507Rotavirus Infections · Taiwan | 3 | Completed | GlaxoSmithKline | Jun 1, 2008 | 230 |
| NCT00508261Meningococcal Infections · Austria, Germany, Greece | 3 | Completed | GlaxoSmithKline | May 26, 2008 | 793 |
| NCT00489554Streptococcal Infections · Mexico | 3 | Completed | GlaxoSmithKline | Mar 31, 2008 | 230 |
| NCT00463437Hepatitis B · Germany, Poland, Spain | 3 | Completed | GlaxoSmithKline | Jan 21, 2008 | 1,437 |
| NCT00432042Chickenpox · Germany, Italy | 3 | Completed | Merck | Mar 27, 2008 | 955 |
| NCT00390910Streptococcal Infections · Greece, Spain | 3 | Completed | GlaxoSmithKline | Jul 2, 2007 | 286 |
| NCT00366366Hepatitis B | 3 | Completed | GlaxoSmithKline | Sep 2002 | 150 |
| NCT00370318Rotavirus Infections · Czech Republic | 3 | Completed | GlaxoSmithKline | 400 | |
| NCT00294294Fever | 4 | Completed | Pfizer | Dec 2006 | 300 |
| NCT00289796Hepatitis B · Germany | 2 | Completed | GlaxoSmithKline | Apr 2006 | 121 |
| NCT00325143Haemophilus Infections · Singapore | 3 | Completed | GlaxoSmithKline | Feb 1, 2007 | 702 |
| NCT00196976Meningococcal Infections · Austria, Greece | 2 | Completed | GlaxoSmithKline | Mar 1, 2006 | 461 |
How it is read
Names in the registry
- “Infanrix hexa”, 10 entries
- “DTPa-HBV-IPV/Hib”, 3 entries
- “Infanrix™ hexa”, 3 entries
- “Infanrix Hexa”, 2 entries
- “DTPa-HBV-IPV/Hib (Infanrix hexa™)”, 2 entries
Conditions, from the studies’ own filings
- Hepatitis B, 8 studies
- Diphtheria, 3 studies
- Streptococcal Infections, 3 studies
- Poliomyelitis, 3 studies
- Meningococcal Infections, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.